Diabetologische Schwerpunktpraxis Pirna
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Diabetologische Schwerpunktpraxis Pirna, cardiovascular research focuses on people with established cardiovascular disease, high cardiovascular risk, and hypertension. The trials are designed to assess new approaches that may help lower LDL cholesterol, reduce heart failure events, and prevent major complications such as heart attack and stroke.
- Testing treatments for better control of cholesterol in people with atherosclerotic disease
- Evaluating therapies aimed at lowering the risk of heart failure and cardiovascular death
- Studying blood-pressure-focused care for patients with difficult-to-control hypertension
These studies reflect a strong interest in improving long-term cardiovascular protection through more effective risk reduction and preventive treatment strategies.
Nutritional and Metabolic Diseases
Clinical research in the area of nutritional and metabolic diseases centers on type 2 diabetes mellitus, obesity, and related cardiometabolic risk. The trials explore whether newer treatments can improve weight management, support diabetes care, and reduce the chance of serious cardiovascular outcomes in people living with metabolic disease.
- Assessing therapies for people with type 2 diabetes and elevated cardiovascular risk
- Studying weight-management approaches in adults with obesity or overweight
- Exploring options that may improve both metabolic control and broader heart health
This research area highlights the link between diabetes, body weight, and cardiovascular prevention, with a focus on better everyday disease management and long-term health outcomes.
Skin and Connective Tissue Diseases
The site also contributes to research on skin and connective tissue diseases, especially diabetic foot ulcers. These studies aim to improve wound healing, test the safety and tolerability of new topical treatments, and increase the chance of complete wound closure in patients with hard-to-heal ulcers.
- Investigating new options for diabetic foot ulcer care
- Evaluating whether treatment can support faster and more complete wound closure
- Focusing on safety and tolerability in patients with non-healing foot wounds
This work is especially relevant for people with diabetes, where improved wound care can help reduce complications and support better quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diabetologische Schwerpunktpraxis Pirna
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase-2, multi-centre, prospective, randomized, standard-of-care plus placebo-controlled, patient and central evaluator blinded, parallel arm, clinical study to evaluate safety, tolerability and efficacy of the recommended phase-2 dose of AUP1602-C in two dosing frequencies as a topical treatment for non-healing neuro-ischemic diabetic foot ulcers | Aurealis Oy | Phase II | Not Recruiting | Jul 2023 | Oct 2025 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rosuvastatin | 2 | Unknown | 2022-04-08 | 2024-06-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.